Women in their childbearing years are significantly less likely than men in the same age range to be given disease-modifying therapies for MS.
Despite evidence supporting the safety of disease-modifying therapies (DMTs) during pregnancy, women with multiple sclerosis (MS) in their childbearing years are significantly less likely than men in the same age range to receive these typically most... [6136 chars]